The JNC 7: Stepped care is alive and well

Journal of Clinical Hypertension

Volumn 5, Issue 3, 2003, Pages 187-195

  Moser, Marvin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; METHYLDOPA; PROPRANOLOL; RAUWOLFIA ALKALOID; RESERPINE; SODIUM; THIAZIDE DIURETIC AGENT;

ALCOHOL CONSUMPTION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; EXERCISE; GENERAL PRACTITIONER; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIFESTYLE; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT COMPLIANCE; RISK FACTOR; SODIUM RESTRICTION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION; BLOOD PRESSURE; DIET; DRINKING BEHAVIOR; DRUG EFFECT;

ALCOHOL DRINKING; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIET; DIET, SODIUM-RESTRICTED; EXERCISE; HUMANS; HYPERTENSION;

EID: 0141798858     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.02565.x     Document Type: Editorial

References (18)

1. Joint National Committee. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255-261.
2. Joint National Committee. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980;140:1280-1285.
3. Joint National Committee. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144:1045-1057.
4. Joint National Committee. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC IV). Arch Intern Med. 1988;148:1023-1038.
5. Joint National Committee. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1993;153:154-183.
6. Joint National Committee. Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
7. Moser M. Treating hypertension: calcium channel blockers, diuretics, β blockers, ACE inhibitors: is there a difference? J Clin Hypertens (Greenwich). 2000;2(5):301-304.
8. Moser M. Clinical Management of Hypertension. 6th ed. Caddo, OK: Professional Communications; 2002.
9. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
10. Wing LMH, Reifel CM, Ryan P, et al. A comparison of outcomes with angiotensin converting enzyme inhibitors and diuretics for hypertension in the elderly. Australian National Blood Pressure Study 2. N Engl J Med. 2003;348:583-592.
11. Hansson L, Zanchetti A, Carrutyers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Hot Study Group. Lancet. 1998;351:1755-1762.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in patients with Nephropathy Due to Type 2 Diabetes (IDNT). N Engl J Med. 2001;345:851-860.
13. Agodoa L, Appel L, Bakris G, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis. African American Study of Kidney Disease (AASK): a randomized controlled trial. JAMA. 2001;285:2719-2728.
14. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
15. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL). N Engl J Med. 2001;345:861-869.
16. Moser M, Hebert P, Hennekens CH. An overview of the metaanalyses of the hypertension treatment trials. Arch Intern Med. 1991;151:1277-1279.
17. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA. 2003;289:2560-2572.
18. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.